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OBJECTIVES The study was done to assess whether the common polymorphic allele (4G) of the
plasminogen activator inhibitor-1 (PAI-1) gene is associated with coronary artery disease
(CAD) or myocardial infarction (MI).
BACKGROUND Impaired fibrinolytic function has been associated with CAD and MI. Plasminogen activator
inhibitor-1 plays a central role in intravascular thrombosis and thrombolysis; the common
insertion/deletion polymorphism (4G/5G) of PAI-1 has been correlated with altered PAI-1
levels and proposed as a coronary risk factor.
METHODS Blood was drawn and DNA extracted from 1,353 consenting patients undergoing coronary
angiography. The 4G and 5G alleles of PAI-1 were amplified using specific primers.
Amplified products were visualized by staining with ethidium bromide after electrophoresis
in 1.5% agarose.
RESULTS Patient age averaged 63.5 (SD 11.7) years; 70% were men, 28% had a history of MI, 66% had
severe CAD (.60% stenosis), and 23% had no CAD or MI. Overall, the frequency of the 4G
allele was 54.2%, and 78% of patients were 4G carriers. Genotypic distributions were:
4G/4G 5 30.1%, 4G/5G 5 47.9%, and 5G/5G 5 21.8%. Neither carriage of 4G (CAD odds
ratio [OR] 5 1.08 [0.80 to 1.46], MI OR 5 1.11 [0.83 to 1.49]) nor 4G/4G homozygosity
(CAD OR 5 1.07, MI OR 5 0.98) was associated with CAD or MI. In multivariate
analyses, risk factors associated with CAD were (in order): gender, age, smoking, diabetes,
cholesterol, and hypertension; for MI, they were gender, smoking, and cholesterol.
CONCLUSIONS A common PAI-1 polymorphism (4G) was not importantly associated with angiographic
CAD or history of MI in a Caucasian population. Modest risk (i.e., OR ,1.5), especially for
MI, or risk in association with other factors, cannot be excluded. (J Am Coll Cardiol 1999;
34:1778–83) © 1999 by the American College of Cardiology
Plasminogen activator inhibitor-1 (PAI-1) plays a central
role in modulating intravascular thrombosis and thrombol-
ysis (1,2). Impaired fibrinolytic function has been found to
be associated with high levels of circulating PAI-1 levels in
patient groups at risk for premature atherosclerosis, with
documented coronary artery disease (CAD), and with a
history of myocardial infarction (MI) (3–8). A link between
PAI-1 activity and atherogenic metabolic derangements
(i.e., obesity, hypertriglyceridemia, and insulin resistance)
has also been suggested (9,10). Experimental induction of
endothelial injury has been found to stimulate PAI-1
expression, facilitating thrombosis (11). The possibility that
genetically determined variability in PAI-1 expression
might be a predisposing factor to coronary atherogenesis
and thrombosis has been suggested (12).
Recently, a common insertion/deletion polymorphism
(designated 4G/5G) of the promoter region of the PAI-1
gene has received attention as a potential risk factor for
CAD and MI. The deletion allele (PAI-1*4G) has been
associated with the inability to bind a transcriptional repres-
sor protein, resulting in increased PAI-1 mRNA expression
and increased circulating PAI-1 protein levels (12–15). In
initial epidemiological studies, homozygous or heterozygous
carriage of 4G has been reported to be associated variously
with familial CAD, with progression to acute coronary
syndrome (ACS), or with a history of MI, although an
association with CAD per se has been inconsistent (12–16).
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Thus, we prospectively tested this hypothesis in a large,
angiographically defined cohort.
METHODS
Study objectives. We tested whether carriage of the com-
mon polymorphic deletion allele of the PAI-1 gene, 4G, was
associated with CAD or a history of MI.
Diseased and control subjects. Study subjects came from
a consecutive series of clinically stable consenting patients of
any age and either gender undergoing coronary angiogra-
phy. Subjects were enrolled after giving written informed
consent to a blood draw for deoxyribonucleic acid (DNA)
extraction for use in genetic epidemiological studies, as
approved by the hospital’s institutional review board. Indi-
cations for angiography included either suspected CAD or
unrelated conditions requiring angiographic evaluation
(e.g., valvular heart disease or cardiomyopathy). Subjects
were residents of Utah, southwestern Idaho, or southeastern
Wyoming, a region that is primarily of Northern European
(Anglo-Scandinavian) extraction and genetically represen-
tative of North American Caucasians (17).
At the time of angiography, key demographic character-
istics were recorded on standard data forms, including age,
gender, and history of recent or remote MI (18). Coronary
artery disease was assessed by review of angiograms by the
patient’s cardiologist, who was uninformed as to PAI-1
genotype, using a format modified after the Coronary
Artery Surgery Study protocol (18,19). Results were entered
into a computerized database.
Patients were designated to have significant CAD if they
had .60% stenosis of at least one coronary artery or major
branch (n 5 898) and no CAD if ,10% stenosis was
present (n 5 329). Patients with minor CAD (10% to 60%
stenosis; n 5 126) were designated as having “indetermi-
nate” CAD status and excluded from CAD analyses. Recent
or remote MI was reported in 375 patients (347 of whom
had severe, and 15 mild CAD). Patients without MI (n 5
978) served as controls. A second MI comparison, in which
those with severe CAD but without MI also were excluded
as controls, gave similar results.
DNA extraction. Approximately 20 to 30 ml of blood was
withdrawn by venipuncture at the time of coronary angiog-
raphy and collected in EDTA. The leukocyte buffy coat was
separated by centrifugation and genomic DNA extracted
using a standard phenol:chloroform method as previously
described (20,21).
DNA genotyping. To identify the PAI-1 genotypes, poly-
merase chain reaction (PCR) amplification of the promoter
region containing the 4G/5G polymorphism was performed
with the following primers, as previously published (22):
PAI-1: 59 AAG CTT TTA CCA TGG TAA CCC
CTG GT 39
PAI-2: 59 TGC AGC CAG CCA CGT GAT TGT
CTA 39
PAI-4GA: 59 GTC TGG ACA CGT GGG GA 39
PAI-5G: 59 GTC TGG ACA CGT GGG GG 39
Both PAI-1 and PAI-2 amplify a 257-bp (base pair)
product from either allele. The PAI-4G4 specifically am-
plifies the 4G allele, and PAI-5G specifically amplifies the
5G allele.
Amplification reactions were performed in 15-ml volumes
and contained both the PAI-1 and PAI-2 primers and
either the PAI-4GA or the PAI-5G primer. A hot-start
protocol was used, beginning with a 94°C hold for 5 min
followed by 40 cycles, each consisting of 1-min denaturation
at 94°C, an annealing segment at 58°C for 45 s, and an
extension segment at 72°C for 1 min. An additional
extension for 15 min at 72°C was added after the last cycle,
followed by a 4°C chill. The products were visualized by
electrophoresis through a 1.5% agarose gel containing
ethidium bromide at a concentration of 0.5 mg/ml. Each
successful reaction produced the expected 257-bp control
band and an additional band in either the PAI-4G4- or
PAI-5G-containing reaction. Positive controls of sequence-
verified genotype were included in each run. Representative
gels for the three genotypes are shown in Figure 1.
Statistical planning and analysis. Power calculations in-
dicated that to determine whether carriage of the 4G
polymorphic allele in the PAI-1 gene was associated with
CAD or MI with an odds ratio (OR) of at least 1.5 with a
power of 80% at a 2-sided alpha level of 0.05 in a population
with a carriage rate of the 4G allele of ’75% would require
samples of about 540 subjects per group (GB Stat for
Windows). Accordingly, we assembled and studied a pop-
ulation of 1,353 subjects; 66% had severe CAD and 28%, a
history of MI.
Allelic and genotypic frequencies were determined from
observed counts. Comparisons between allelic and geno-
typic frequencies used chi-square analysis. Associations were
assessed as OR and 95% confidence intervals (CI). Univar-
Abbreviations and Acronyms
ACS 5 acute coronary syndrome
bp 5 base pair
CAD 5 coronary artery disease
DNA 5 deoxyribonucleic acid
EDTA 5 ethylenediaminetetraacetic acid
MI 5 myocardial infarction
OR 5 odds ratio
PAI 5 plasminogen activator inhibitor
PCR 5 polymerase chain reaction
VLDL 5 very low density lipoprotein
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iate and multivariate logistic regression was used to deter-
mine crude ORs for the genetic marker and adjusted ORs,
conditioned on six major CAD risk factors: age, gender,
smoking status, diabetic status, history of hypertension, and
cholesterol concentration (SPSS 6.1, Chicago, Illinois).
RESULTS
Characteristics of the patient groups. A total of 1,353
subjects was studied. Age averaged 63.5 (SD 11.7) years
(range 16 to 93); 375 had a history of MI, and 898 had
severe CAD. Key patient characteristics are summarized by
disease subgroup in Table 1. The CAD group differed from
no-CAD controls in being older, more frequently male,
diabetic, smokers, and hypertensive (by history). Those with
MI were more frequently men and smokers but had lower
(post-MI) blood pressure.
Genotypic and allelic frequencies among controls and
diseased subjects. Genotypic and allelic frequencies for
the study groups are shown in Table 2. Genotypic
distributions in the control groups conformed with
Hardy-Weinberg expectations. The PAI-1*4G allelic fre-
quency overall was 54.2%, and it did not differ between
control and diseased groups. The PAI-1*4G allele was
carried overall by 78.2% of subjects, with similar rates in
the control and diseased groups. The 4G carriage was
associated with an OR 5 1.08 (CI 0.80 to 1.46) for CAD
and an OR 5 1.11 (CI 0.83 to 1.49) for MI (dominant
model). The homozygotic 4G/4G genotype occurred in
30.2% of study subjects; again, there were no differences
in frequency among subgroups. The 4G/4G homozygos-
ity was associated with an OR 5 1.07 (CI 0.75 to 1.52)
for CAD and an OR 5 0.98 (0.70 to 1.38) for MI
(recessive model). Co-dominant modeling (assuming a
dose-related effect of 4G) also failed to find an association
of genotype with CAD (OR 5 0.97) or MI (OR 5 1.02).
Multivariate logistic modeling for CAD and MI. To
simultaneously condition associations with CAD or MI on
seven key baseline characteristics, including genotype, mul-
tivariate conditional logistic regression was performed.
With forced entry of 4G carrier status together with age,
diabetes, hypertension, gender, and smoking status, the
adjusted OR 5 1.12 (0.83 to 1.51) for CAD and 1.06 (0.76
to 1.47) for MI. When cholesterol also was entered in the
smaller cohort of CAD patients and controls with available
levels (n 5 774), the adjusted OR 5 1.08 (0.75 to 1.54) for
CAD and OR 5 1.28 (0.83 to 1.97) for MI. None of the
adjusted ORs differed significantly from 1.
The final logistic model for CAD included, in order of
independent strength of association, gender, age, smoking
status, diabetes, and history of hypertension (Table 3). For
the cohort with measured cholesterol levels, the indepen-
dent associates were gender, age, cholesterol levels, and
history of hypertension.
Figure 1. Examples of polymorphic genotyping using polyacryl-
amide gel electrophoresis of PCR amplification products. Gel A is
a 5G homozygote; gel B is a 4G/5G heterozygote; gel C is a 4G
homozygote. The higher molecular weight band (257 bp) in each
gel run is the positive control.
Table 1. Characteristics of Diseased and Control Patients
Characteristic









No. 898 329 375 978
Age (yr) (mean 6 SD) 65.2 6 10.9 59.2 6 12.6*** 63.7 6 11.6 63.5 6 11.7
Gender (% men) 77.7 52.4*** 79.4 66.5***
Hypertension (%) 56.8 46.5** 56.3 53.2
Systolic BP (mm Hg) 144 6 26 143 6 24 135 6 25 147 6 25***
Diastolic BP (mm Hg) 79 6 13 81 6 12 77 6 13 81 6 13***
Smoker (%) 24.2 15.5** 29.6 18.4***
Diabetes (%) 17.6 12.8* 16.3 16.2
Cholesterol (mg/dl) 199 6 49 196 6 52 192 6 40 202 6 55**
(n) (606) (170) (266) (570)
*p , 0.05; **p , 0.01; ***p , 0.001 between groups.
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For MI, the final logistic model included gender and
smoking status (Table 3). For the cohort with measured
cholesterol levels (n 5 834), the model included smoking,
gender, and cholesterol.
DISCUSSION
Summary of study results. In a large, angiographically
defined population, no significant association was found
between the PAI-1 4G/5G insertion/deletion polymorphism
and the presence of CAD or MI (recent or remote). The
point estimates of the ORs suggested associations with 4G
carriage of the order of only 1.0 to 1.3, either unadjusted or
adjusted for common baseline risk factors. Associations with
ORs .1.5 were excluded with 95% confidence. The integ-
rity of the analyses was supported by the finding of associ-
ations of CAD and MI with well-established risk factors
such as age, male gender, smoking, cholesterol, diabetes,
and history of hypertension (Table 3).
Pathophysiologic importance of PAI-1. Impaired fi-
brinolytic activity is now known to play an integral role in
atherothrombotic vascular disease (1–3,23). Impaired
plasma fibrinolytic activity has been shown to correlate with
atherothrombotic events (e.g., MI, stroke) but less clearly
with extent of atherosclerosis, although histologic athero-
sclerosis is associated with impaired in situ fibrinolytic
activity (3,24–29). Polymorphisms of specific fibrinolysis-
related genes (e.g., PAI-1) may regulate protein synthesis or
transcriptional response to metabolic factors (e.g., insulin,
triglycerides) (13,26,30–34), contributing to fibrinolytic
activity and risk of thrombosis.
In patients with CAD, especially with a history of MI or
other ACS, fibrinolytic activity is impaired at rest and after
exercise, and this impairment is associated with increases in
circulating PAI-1 (3,5,7,8,27–29). Moreover, PAI-1 activ-
ity is raised in diabetics and is particularly high in those with
MI (5,6). Also, PAI-1 activity correlates positively with very
low density lipoprotein (VLDL) triglycerides and negatively
with insulin sensitivity (9,27,28). In addition, PAI-1 has
been proposed as a link among obesity, insulin resistance,
and cardiovascular disease (10). High levels of PAI-1, as
well as fibrinogen, are predictors of MI (4,27–29).
Expression of PAI-1 may be genetically influenced.
Indeed, the PAI-1*4G deletion polymorphism, carried by
three-quarters of Caucasians, has been associated with
increased circulating PAI-1 levels (14,15,30,32). The
4G/5G polymorphism is defined by an insertion or deletion
of a guanine in the promoter region of the PAI-1 gene, 675
bp upstream of the transcription start site (12). Thrombosis
induced by endothelial injury stimulates PAI-1 gene expres-
sion and local PAI-1 synthesis, which may facilitate throm-
botic progression (11). The possibility that 4G carriage may
accelerate CAD or its progression to MI or other ACS has
stimulated this and other published studies.
Table 2. Genotypic Distributions and Allelic Frequencies of PAI-1*4G Polymorphism Among Patients and Controls
Group 4G/4G n (%) 4G/5G n (%) 5G/5G n (%) 4G Allele 5G Allele
CAD/Controls
CAD (n 5 898) 267 (29.7) 433 (48.2) 198 (22.0) 967 (53.8) 829 (46.2)
No CAD (n 5 329) 97 (29.5) 155 (47.1) 77 (23.4) 349 (53.0) 309 (47.0)
MI/Controls
MI (n 5 375) 105 (28.0) 193 (51.5) 77 (20.5) 403 (53.7) 347 (46.3)
No MI (n 5 978) 303 (31.0) 457 (46.7) 218 (22.3) 1063 (54.3) 893 (45.7)
Table 3. Multivariate Logistic Regression Models for CAD and MI
Variable B SE Wald df Sig R
Exp (B)
(OR)
Predictive model for CAD
Gender (M) 1.479 0.154 91.80 1 0.0000 0.251 4.386
Age/yr 0.0576 0.0064 81.00 1 0.0000 0.236 1.059
Smoker 0.626 0.186 11.280 1 0.0008 0.081 1.871
Diabetes 0.599 0.208 8.277 1 0.0040 0.0664 1.820
Hypertension 0.354 0.143 6.121 1 0.013 0.0538 1.424
Constant 23.948 0.446 78.394 1 0.0000
Predictive model for MI
Gender (M) 0.589 0.147 16.13 1 0.0001 0.0941 1.802
Smoker 0.538 0.142 14.31 1 0.0002 0.829 1.712
Constant 21.52 0.129 138.93 1 0.0000
Modeling used Backward Conditional Logistic Regression (SPSS 6.1 for Power Macintosh), initially entering age (in years), and dichotomous status (yes/no) for diabetes,
hypertension, gender 5 male (M), and PAI-1*4G carriage. Cholesterol level (in mg/dl) also was entered in a separate analysis, and was selected as an independent multivariate
predictor in the CAD/control cohort with lipid data (n 5 774) (Exp[B] 5 1.0056/mg/dl, p 5 0.007), together with gender, age, and hypertension. M 5 male; yr 5 years.
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Synthesis of published and present studies. Our finding
of no significant association of PAI-1*4G with MI or CAD
contrasts with four smaller studies (12,14–16) but is in
keeping with another larger, prospective study (30). One
positive study showed only an indirect (familial) association
(16); another used an exploratory approach and an uncon-
ventional definition of ACS (15); the association in a third
study was limited to patients with MI under the age of 45
(12). Despite an insignificant result, our study’s adjusted
OR of 1.28 is similar to the OR of 1.29 reported by
Margaglione et al. (16). The 95% CI of Ossei-Gerning’s
(14) study (OR 5 2.0, lower CI bound, 1.1) and ours
(OR 5 1.1 to 1.3, upper CI bound, 1.5–2.0) broadly
overlap. In Etude Cas Tenoin de infarctus du Myocarde, a
relatively large case-control study, the 4G allele showed a
dose-related correlation with plasma PAI-1 levels but no
association with MI (allele frequencies 0.55 in cases, 0.54 in
controls) (30). In a mouse atherogenesis model, no signifi-
cant differences were found in aortic atherosclerosis between
PAI-1 overexpressing and deficient groups (35). Taken
together, these observations are consistent with PAI-1*4G
exerting at most a modest independent effect on athero-
thrombotic events occurring late in disease progression
(OR # 1.5–2.0), with the polymorphism probably requiring
interaction with other genetic and environmental factors.
Study strengths and limitations. Study strengths include
its relatively large size and angiographic diagnosis. Signifi-
cant genetic selection bias appears unlikely in the no-CAD
“controls” undergoing angiography, but our findings should
apply in any case to patients presenting for evaluation of
suspected ischemic heart disease. Our study was “retrospec-
tive” with respect to MI events, raising the possibility of
changes in prevalence of PAI-1*4G among cases compared
with controls due to differential survival rates after MI based
on PAI-1*4G carrier status. Against this is the observation
that PAI-1*4G allelic frequencies (53% to 54%) are similar
in other published studies of different design (12–
14,16,26,30). Nevertheless, prospective, matched case-
control studies would be of interest. Finally, conditional
logistic regression was performed to adjust for differences in
baseline factors between cases and controls; adjustment
resulted in only minor changes in the OR.
Conclusions. In a large North American population of
European extraction, no significant association with CAD
or MI of a common polymorphism (4G/5G) of the pro-
moter region of the PAI-1 gene was found. These study
results, angiographically determined, address inconsistencies
in earlier association studies (10–16,25–27). The pathogen-
esis of both CAD and MI is complex and multifactorial,
with multiple interacting (and compensating) environmen-
tal and genetic determinants, and PAI-1 variants might
affect risk only in concert with other specific environmental
and genetic factors (e.g., multiple gene variants combined in
specific haplotypic patterns). Hence, further research on
coagulation-related genetic factors is warranted, including
prospective studies of 4G/5G and other PAI-1 polymor-
phisms in large populations at risk for atherothrombotic
events.
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